Report cover image

Vascular Anomalies Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20147078

Description

Vascular anomalies refer to a broad spectrum of abnormalities that involve blood vessels. It includes vascular malformations and proliferating vascular tumors. The development of innovative medications like propranolol for infantile hemangiomas and advancements in sclerotherapy agents are significantly contributing to the pipeline expansion for vascular anomalies drugs. Moreover, robust support from regulatory bodies is anticipated to encourage further investments in novel treatments for this condition.

Report Coverage

The Vascular Anomalies Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into vascular anomalies therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Vascular Anomalies. The vascular anomalies report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The vascular anomalies pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with vascular anomalies treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to vascular anomalies.

Vascular Anomalies Drug Pipeline Outlook

Vascular anomalies are a group of disorders or abnormalities of the vascular system, affecting blood vessels, lymph vessels, or both. This condition can occur as a result of abnormal development of the blood vessels, leading to localized defects such as birthmarks or growths that can be disfiguring. The symptoms vary depending on the type of malformation. Vascular anomalies can cause functional or cosmetic problems. It can occur in any part of the body but is usually found in the head and neck.

Vascular anomalies therapeutics include low molecular weight heparin that can help in treating pain or preventing blood clots. Sclerotherapy is also used for shrinking the malformation or closing off abnormal veins. Additionally, advancements in imaging technologies such as MRI, CT scans, and ultrasound, along with adherence to vascular anomalies treatment guidelines, are expected to support the pipeline growth in the coming years.

Vascular Anomalies Epidemiology

Vascular anomalies are a relatively common disorder of the endothelium, affecting arteries, veins, capillaries, or lymphatics. The prevalence of vascular anomalies is estimated to be around 5% . The condition is classified into tumors or malformations. According to a review article published in Circulation Research (2021), vascular malformations are reported to affect approximately 1% to 1.5% of the population.

Vascular Anomalies – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of vascular anomalies drug candidates based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase:
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class

EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:
  • Recombinant Fusion Proteins
  • Small Molecule
  • Monoclonal Antibody
  • Peptide
  • Polymer
  • Gene Therapy
By Route of Administration

EMR’s vascular anomalies report assessment covers 50+ drug analyses based on the route of administration.
  • Oral
  • Parenteral
  • Others
Vascular Anomalies – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials, with a substantial number of vascular anomalies emerging drugs undergoing clinical development.

Vascular Anomalies – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under vascular anomalies pipeline analysis include recombinant fusion proteins, small molecule, monoclonal antibody, peptide, polymer, and gene therapy. The vascular anomalies report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for vascular anomalies.

Vascular Anomalies Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the vascular anomalies drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed vascular anomalies therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in vascular anomalies clinical trials:
  • Palvella Therapeutics, Inc.
  • Novartis Pharmaceuticals
  • Protara Therapeutics
  • Inozyme Pharma
  • Vascular Therapies, Inc.
  • Vaderis Therapeutics AG
Vascular Anomalies – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for vascular anomalies. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of vascular anomalies drug candidates.

Drug: Sirolimus

The objective of this multicenter clinical trial is to investigate the efficacy and safety of the vascular anomalies drug candidate Sirolimus in patients who are refractory to standard care. The study is under Phase III clinical development and has an estimated 250 participants.

Drug: Alpelisib

Sponsored by Novartis Pharmaceuticals, this Phase II/III multi-center trial aims to examine the efficacy of Alpelisib in the treatment of lymphatic malformations associated with a PIK3CA mutation in pediatric and adult patients. The interventional study has enrolled about 230 subjects and is expected to be completed by May 2030.

Reasons To Buy This Report

The Vascular Anomalies Drug Report provides a strategic overview of the latest and future landscape of treatments for vascular anomalies. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within vascular anomalies pipeline insights.

Key Questions Answered in the Vascular Anomalies – Pipeline Insight Report
  • Which companies/institutions are leading the vascular anomalies drug development?
  • What is the efficacy and safety profile of vascular anomalies pipeline drugs?
  • Which company is leading the vascular anomalies pipeline development activities?
  • What is the current vascular anomalies commercial assessment?
  • What are the opportunities and challenges present in the vascular anomalies drug pipeline landscape?
  • What is the efficacy and safety profile of vascular anomalies pipeline drugs?
  • Which company is conducting major trials for vascular anomalies drugs?
  • Which companies/institutions are involved in vascular anomalies collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in vascular anomalies?
Related Reports

Vascular Malformations Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Vascular Anomalies
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Vascular Anomalies
3.5 Diagnosis
3.6 Treatment
4 Patient Profile: Vascular Anomalies
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Vascular Anomalies: Epidemiology Snapshot
5.1 Vascular Anomalies Incidence by Key Markets
5.2 Vascular Anomalies – Patients Seeking Treatment in Key Markets
6 Vascular Anomalies: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Vascular Anomalies: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Vascular Anomalies, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Vascular Anomalies Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Vascular Anomalies Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Sirolimus
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: Alpelisib
10.2.3 Drug: QTORIN 3.9% Rapamycin Anhydrous Gel
10.2.4 Other Drugs
11 Vascular Anomalies Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: Alpelisib, Drug: Mirdametinib
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Biological: TARA-002
11.2.3 Other Drugs
12 Vascular Anomalies Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug 1
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Vascular Anomalies Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Vascular Anomalies, Key Drug Pipeline Companies
14.1 Palvella Therapeutics, Inc.
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Novartis Pharmaceuticals
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Protara Therapeutics
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Inozyme Pharma
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Vascular Therapies, Inc.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Vaderis Therapeutics AG
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us